296 related articles for article (PubMed ID: 25594854)
1. Impact of anti-inflammatory therapies, xanthine oxidase inhibitors and other urate-lowering therapies on cardiovascular diseases in gout.
Richette P; Frazier A; Bardin T
Curr Opin Rheumatol; 2015 Mar; 27(2):170-4. PubMed ID: 25594854
[TBL] [Abstract][Full Text] [Related]
2. Improving cardiovascular and renal outcomes in gout: what should we target?
Richette P; Perez-Ruiz F; Doherty M; Jansen TL; Nuki G; Pascual E; Punzi L; So AK; Bardin T
Nat Rev Rheumatol; 2014 Nov; 10(11):654-61. PubMed ID: 25136785
[TBL] [Abstract][Full Text] [Related]
3. Gout.
Rott KT; Agudelo CA
JAMA; 2003 Jun; 289(21):2857-60. PubMed ID: 12783917
[No Abstract] [Full Text] [Related]
4. Influence of urate-lowering therapies on renal handling of uric acid.
Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
[TBL] [Abstract][Full Text] [Related]
5. Drugs for gout.
Med Lett Drugs Ther; 2014 Mar; 56(1438):22-4. PubMed ID: 24791281
[No Abstract] [Full Text] [Related]
6. Update on emerging urate-lowering therapies.
Chohan S; Becker MA
Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
[TBL] [Abstract][Full Text] [Related]
7. Colchicine and other drugs for gout.
Med Lett Drugs Ther; 2009 Nov; 51(1326):93-4. PubMed ID: 20224523
[No Abstract] [Full Text] [Related]
8. [Medications against gout].
Gast LF; Cats A
Ned Tijdschr Geneeskd; 1988 Oct; 132(40):1827-31. PubMed ID: 3185770
[No Abstract] [Full Text] [Related]
9. Advances in the management of gout and hyperuricaemia.
Hoskison TK; Wortmann RL
Scand J Rheumatol; 2006; 35(4):251-60. PubMed ID: 16882587
[TBL] [Abstract][Full Text] [Related]
10. Gout: a comprehensive review.
Rymal E; Rizzolo D
JAAPA; 2014 Sep; 27(9):26-31. PubMed ID: 25102078
[TBL] [Abstract][Full Text] [Related]
11. Gout: 'a disease of plenty'.
Rasaratnam I; Christophidis N
Aust Fam Physician; 1995 May; 24(5):849-51, 855-6, 859-60. PubMed ID: 7794148
[TBL] [Abstract][Full Text] [Related]
12. A review of phytotherapy of gout: perspective of new pharmacological treatments.
Ling X; Bochu W
Pharmazie; 2014 Apr; 69(4):243-56. PubMed ID: 24791587
[TBL] [Abstract][Full Text] [Related]
13. Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares.
Soskind R; Abazia DT; Bridgeman MB
Expert Opin Pharmacother; 2017 Aug; 18(11):1115-1125. PubMed ID: 28658988
[TBL] [Abstract][Full Text] [Related]
14. Management of acute and chronic gouty arthritis: present state-of-the-art.
Schlesinger N
Drugs; 2004; 64(21):2399-416. PubMed ID: 15481999
[TBL] [Abstract][Full Text] [Related]
15. Refractory gout: what is it and what to do about it?
Fels E; Sundy JS
Curr Opin Rheumatol; 2008 Mar; 20(2):198-202. PubMed ID: 18349751
[TBL] [Abstract][Full Text] [Related]
16. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.
Schumacher HR
Expert Opin Investig Drugs; 2005 Jul; 14(7):893-903. PubMed ID: 16022578
[TBL] [Abstract][Full Text] [Related]
17. Uric acid lowering therapy in cardiovascular diseases.
Volterrani M; Iellamo F; Sposato B; Romeo F
Int J Cardiol; 2016 Jun; 213():20-2. PubMed ID: 26386814
[TBL] [Abstract][Full Text] [Related]
18. [The clinical picture of gout is changing].
Julkunen H; Konttinen YT
Duodecim; 2010; 126(12):1477-85. PubMed ID: 20617751
[TBL] [Abstract][Full Text] [Related]
19. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
20. The current state of care in gout: Addressing the need for better understanding of an ancient disease.
Zychowicz ME; Pope RS; Graser E
J Am Acad Nurse Pract; 2010 Nov; 22 Suppl 1():623-36. PubMed ID: 21054636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
